Lindar the Panerusck Reduction Act of 1995, on persons are required in reserv

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

 Application Number
 10668672

 Filing Date
 2003.09.23

 First Named Inventor
 Samuel I. STUPP et al.

 Art Unit
 1656

 Examine Name
 Nazimene Marile Noakes

 Adtomey Docket Number
 NANO 105 USZ (NU 22074)

U.S.PATENTS							Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C	Date	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wis	h to a	d additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Rele			,Columns,Lir ant Passages s Appear		
	1										
If you wis	h to a	d additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	buttor	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patente Applicant of cited Document	or	Pages,Colun where Relevi Passages or Figures Appe	ant Relevant	TS
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s).						Τs				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10668672		
Filing Date		2003-09-23		
First Named Inventor Samu		el I. STUPP et al.		
Art Unit		1656		
Examiner Name Suzar		nne Marie Noakes		
Manager Dealest Number		NAMO 405 LICO (NILLOODZA)		

Nomizu, Molyochi, Kaco Yamamza, Hyada K. Koleman, and Yoshihlo Yamada. August 1, 1993. "Multimore From of Tyrile-Gy-S-red (PICSSI) Peptide Enhance the Inhibition of Tumor Growth and Metastasis." Cancer Research. Vol. 53, pp. 3499-3491.							
Jin, Young-Gu and K. J. Chang. February 26, 2001. "Mechanism for the Enhanced Diffusion of Charged Oxygen Ions in SiO2." Physical Review Letters. Vol. 86, No. 9, pp. 1753-1756.							
3 Matsul, Hroahi and Robert MacCuspie. December 2001. "Metalispopphyrn Nanotube Fabrication Using Peptide Nanotubes as Templates." Nano Letiers. Vol. 1, No. 12, pp. 671-675.							
Invine, Darrell J. and Anne M. Meyes. 2001. "Nanoscale Clustering of RGD Pephdes at Surfaces Using Comb Poymers. 1. Synthesis and Characterization of Comb Thin Films." Biomeoromolecules. Vol. 2, No. 1, pp. 85-94.							
5 Matsui, Hroati, Precia Porrate, and Gary E. Douberly, Jr. 2001. "Protein Tubule Immobilization on Self-Assembled Monolayers on Au Substrates." Nano Letters. Vol. 1, No. 9, pp. 461-464.							
Stocik, Joseph M., Josepha T. Moore, and David W. Whight. March 2002. Monoclonal Antibody Recognition of Histoline-Rich Peptide Encapsulated Nanoclasters." Nano Letters. Vol. 2, No. 3, pp. 169-173.							
Shih, Sheng-Ming, Wei-Fang Su, Yuf-Juan Lin, Cen-Shawn Wu, and Chil-Dong Chen. 2002. "Two-Dimensional 7 Array of Sef-Assembled Gold and Suthar-Containing Fullerene Nanoperfoles." Langmair, Vol. 18, No. 8, pp. 5022-5035.							
8 Wong, Michael S. Jennifer N. Cha, Krycung-Shin Choi, Timothy J. Deming, and Gallen D. Study. 2002. "Assembly of Nanoparticles into Hollow Spheres Using Block Copolypoptides." Nano Letters. Vol. 2, No. 6, pp. 583-587.							
*AccessSomeno Search Results. Arephiphile: *Accessed online May 7, 2007. http://www.accesssoence.com/search/ search? 9 location-tifected.arephile-Spappre-private/Scategories-dictorarys/scategoral-dictorarys/stot/-amph-phile McGraw-HII Encyclopated of Scance & Technology Chilan.							
f you wish to add additional non-patent literature document citation information please click the Add button Add							

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

lication Number		10668672	
Filing Date		2003-09-23	
t Named Inventor	Samu	amuel I. STUPP et al.	
Art Unit		1656	
miner Name	Suzan	uzanne Marie Noakes	
Attorney Docket Number		NANO 105 US2 (NU 22074)	
t	Date Named Inventor nit niner Name	Date Samu	

See find. Codes of USPTO Planto Tocuments at view, USPTO, DOV or MFEP 901.04. * Enter office that its such the document, by the two-later code, VIPO Standard ST3.3. ** Frequence parted consomers, the includion of the parent of temper result precedence the senial number of the parted consomer. **
**Incl of Coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **
Applicant is to place a check mark here if English targuage translations a statistical.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10668672		
Filing Date		2003-09-23		
First Named Inventor	Samuel I. STUPP et al.			
Art Unit		1656		
Examiner Name	Suzanne Marie Noakes			
Attorney Docket Number		NANO 105 US2 (NU 22074)		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 an	d 1.98 to make the	appropnate selection	h(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement, was cited in a communication from a design parted rollic in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to item individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) and the contraction of the contraction

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Non

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Maria L. Maebius/	Date (YYYY-MM-DD)	2007-07-20
Name/Print	Maria I Maehius	Registration Number	42.967

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1450, Alexandrin, V.S. 2311-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1450, Alexandrin, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.